Mixed micellar nanoparticle of amphotericin B and poly styrene-block-poly ethylene oxide reduces nephrotoxicity but retains antifungal activity

Archives of Pharmacal Research

Volumn 30, Issue 10, 2007, Pages 1344-1349

  Han, Kun ^a   Miah, M A Jalil ^a   Shanmugam, Srinivasan ^b   Yong, Chul Soon ^b   Choi, Han Gon ^b   Kim, Jung Ae ^b   Yoo, Bong Kyu ^b  

^a Chungbuk National University   (South Korea)

^b Yeungnam University   (South Korea)

Author keywords

Amphotericin B; Mixed micellar nanoparticle; Nephrotoxicity; Poly styrene block poly ethylene oxide; Self aggregation

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; NANOPARTICLE; POLYSTYRENE DERIVATIVE;

ANIMAL; ARTICLE; CANDIDA ALBICANS; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; DRUG FORMULATION; GROWTH, DEVELOPMENT AND AGING; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; KIDNEY FUNCTION TEST; MALE; MICELLE; MICROBIOLOGICAL EXAMINATION; PARTICLE SIZE; PATHOLOGY; PATHOPHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT; SURFACE PROPERTY;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MICELLES; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYSTYRENES; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES;

EID: 35649004977     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02980276     Document Type: Article

References (20)

1. Barwicz, J., Christian, S., and Gruda, L1 Effects of the aggregation state of amphotericin B on its toxicity to mice. Antimicrob. Agents Chemother., 36, 2310-2315 (1992).
2. Bolard, J., Legrand, P., Heitz, F., and Cybulska, B., One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry, 30, 5707-5715 (1991).
3. Brajtburg, J., Elberg, S., Travis, S. J., and Kobayashi, G S., Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles. Antimicrob. Agents Chemother, 38, 294-299 (1994).
4. Dewhurst, P. F., Lovell, M. R., Jones, J. L., and Richards, R. W., Organization of Dispersions of a Linear Diblock Copolymer of Polystyrene and Polyethylene oxide) at the Air-Water Interface Macromolecules, 31, 7851-7864 (1998).
5. Ernst, C., Grange, J., Rinnert, H., Dupont, G., and Lematre, J., Structure of amphotericin B aggregates as revealed by UV and CD spectroscopies. Biopolymers, 20, 1575-1588 (1981).
6. Herbrecht, R., Nivoix, Y., Fohrer, C., Natarajan-Ame, S., and Letscher-Bru V., Management of systemic fungal infections: alternatives to itraconazole. J. Antimicrob. Chemother., 56 (Suppl 1), i39-i48 (2005).
7. Kayser, O., Lemke, A., and Hernandez-Trejo, N., The impact of nanobiotechnology on the development of new drug delivery systems. Curr. Pharm. Biotechnol., 6, 3-5 (2005).
8. Kleinberg, M., What is the current and future status of conventional amphotericin B? Int. J. Antimicrob. Agents, 27 (Suppl 1), 12-16 (2006).
9. Mullen, A. B., Carter, K. C., and Baillie, A. J., Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.Antimicrob. Agents Chemother., 41, 2089-2092 (1997).
10. Olson, J. A, Adler-Moore, J. P., Schwartz, J., Jensen, G. M., and Proffitt, R. T., Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimbrob. Agents Chemother., 50, 2122-2131 (2006).
11. Rinnert, H., Thirion, C., Dupont, G, and Lematre J., Structural studies on aqueous and hydro alcoholic solutions of a polyene antibiotic: amphotericin B.Biopolymers, 16, 2419-2427(1977).
12. Saxena, S. and Ghosh, P. C., Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigatus infected mice. Pharm. Res., 17, 1236-1242 (2000).
13. Tancrede, P., Barwicz, J., Jutras, S., and Gruda, I., The effect of surfactants on the aggregation state of amphotericin B. Biochim. Biophys. Acta., 1030,289-295 (1990).
14. Townsend, R. W., Zutshi, A., and Bekersky, I., The effect of surfactants on the aggregation state of amphotericin B. Drug Metab. Dispos., 29, 681-685 (2001).
15. Uchegbu, I. F., Pharmaceutical nanotechnology: polymeric vesicles for drug and gene delivery. Expert Opin. Drug Deliv., 3, 629-640 (2006).
16. Viudes, A., Peman, J., Canton, E., Ubeda, P., Lopez-Ribot, J. L., and Gobernado, M., Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur. J. Clin. Microbiol. Infect. Dis., 21, 767-774 (2002).
17. Wingard, J. R., Kubilis, P., Lee, L., Yee, G., White, M., Walshe, L., Bowden, R., Anaissie, E., Hiemenz, J., and Lister, J., Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis., 29, 1402-1407 (1999).
18. Yamashita, K., Janout, V., Bernard, E., Armstrong, D., and Regen, S., Micelle/monomer control over the membranedisrupting properties of an amphiphilic antibiotic. J. Am. Chem. Soc., 117, 6249-6253 (1995).
19. Yoo, B. K., Jalil Miah, M. A., Lee, E. S., and Han K., Synthesis of decapeptide of L-aspartic acid and benzyl-L-aspartic acid by solid phase peptide synthesis. Arch. Pharm. Res., 28, 756-760 (2005).
20. Yoo, B. K., Jalil Miah, M. A., Lee, E. S., and Han K., Reduced renal toxicity of nanoparticular amphotericin B micelles prepared with partially benzylated poly-L-aspartic acid. Biol. Pharm. Bull., 29, 1700-1705 (2006).